Eli Lilly is the first health care company to reach a market value of $1 trillion, according to a CNBC report.
Eli Lilly produced weight loss injection drug Zepbound and diabetes treatment Mounjaro. Mounjaro made $6.5 billion in revenue in Eli Lilly’s fiscal third quarter, while Zepbound made $3.5 billion, according to the company. Both are up 109% and 184%, respectively, over the same period last year.
The company’s stock has risen more than 36% this year and is the second non-technology company to reach a $1 trillion valuation in the U.S. Warren Buffett’s Berkshire Hathaway is the other company to reach the milestone.
